ABSTRACT In the past decade, the consumption of psilocybin mushrooms has become a popular therapeutic tool for people looking to deal with mental and emotional health issues. The emerging interest in psilocybin therapy in the global north has led to the development of retreat centers in locations where psilocybin is legal or unregulated. Drawing on ethnograp...
Introduction Psilocybin is a psychedelic drug found in mushrooms, often referred to as magic mushrooms due to its visual and auditory hallucinations effects upon ingestion. It is a Schedule I drug per DEA, and the FDA has not approved psilocybin for medicinal purposes. However, recent studies have shown promising therapeutic use to treat depression. Objectiv...
As the consumers push towards use of natural substances for whole body health increases, and as the dependence upon prescription drugs shows no abatement, substances such as psilocybin (magic mushrooms) have emerged as acceptable methods to treat ailments previously addressed by prescription drugs. In addition to medical solutions provided naturally, many of...
Hallucinogens comprise of a vast amount of substances such as Lysergic Acid Diethylamide, Phenylcyclidine PCP, naturally occurring alkaloid like Belladona and even mushrooms such as psylocybins. Usage of these substances can be traced back to antiquity, serving various purpose such as spiritual rites or even recreational purposes. However, in the modern era,...
BackgroundDespite tetrahydrocannabinol (THC)'s reputation for creating dramatic effects at high doses, empirical work rarely addresses cannabis's impact on subjective responses common to the tryptamine psychedelics. We focused on these effects because they have preceded and covaried with the therapeutic impact of psilocybin in previous work.AimsThe current s...
Abstract We sought to estimate the prevalence of lifetime psilocybin use among a national sample of US adults ages 18 and older and associated demographic/substance use correlates. Pooled data from the 2015-2018 National Survey on Drug Use and Health were utilized among 168,650 individuals 18 years or older. An estimated 9.68% of individuals reported lifetim...
In fall 2020, as the nation elected Joe Biden to be our Forty-Sixth President, Oregon voters also passed a noteworthy new drug law reform. Known as Measure 109, Oregon’s path-breaking law legalizes the use of psilocybin, a hallucinogenic substance found in magic mushrooms. Measure 109 is designed to unlock the therapeutic potential of psilocybin, which advoc...
Use of psilocybin reduces anxiety and depression when used as palliative care in cancer cases. Oregon is poised to legalize this drug for therapeutic use, a revolutionary step forward in the legalization process that will increase the care options for patients.
The psychedelic psilocybin and the entactogen 3,4-methylenedioxymethamphetamine (MDMA) are being scientifically studied again after a long hiatus, and especially for their potential in the treatment of psychiatric disorders. Their profound effect on cognitive, perceptual, and affective processes have led to several clinical studies during the last decade tha...
Introduction: Cannabis has been historically classified as a hallucinogen. However, subjective cannabis effects do not typically include hallucinogen-like effects. Empirical reports of hallucinogen-like effects produced by cannabis in controlled settings, particularly among healthy research volunteers, are rare and have mostly occurred after administration o...
Mikrodosering av psykedeliska droger är den senaste trenden som verkar ha fått en stor spridning, främst bland unga människor för att uppnå ökad produktivitet och kreativitet, men även för att uppnå allmän psykisk hälsa. Denna uppsats lägger fokus på lysergsyradietylamid (LSD) och psilocybin (magic mushroom). Mikrodosering innebär att användaren tar en väldi...
This "Designer Drugs 2.0" issue of Clinical Pharmacology & Therapeutics focuses on novel psychoactive substances, primarily cannabinoids and cathinones, and the repurposing of established psychoactive compounds (e.g., modafinil, psilocybin, lysergic acid diethylamide, and 3,4-methylenedioxymethamphetamine) that simultaneously offer new pharmacotherapies and ...
AimThere have been significant changes in adolescent consumption habits over the past fifteen years. New molecules have been synthesized, new devices created and a number of products have increased in popularity; and as a result clinicians sometimes lack information. We chose to focus on this population because of its vulnerability, as adolescents show low s...
Psilocybin-Research.com
Searchable psilocybin and psilocin bibliometric database.